Todd Pesavento, MD
Nephrology · Columbus, OHNPI 1629085030
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $12,420 of the $20,100 with a category attached, or 61.8%. 4 manufacturers reported payments, led by Argenx US, Inc. at 43.2% of the total. Reporting peaked in 2024 at $8,686 and has fallen 100.0% since, to $2 in 2025. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $804.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$9K
- Sanofi-aventis U.S. LLC$8K
- CSL Behring$3K
- Travere Therapeutics, Inc.$2
Across 89 payments — averaging $2174.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$126K
- Apellis Pharmaceuticals, Inc.$57K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
What the payments were for
- Consulting fees$6,85234%
- Travel & lodging$12,42062%
- Food & beverage$8274%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 8 | $8,686 |
| Sanofi-aventis U.S. LLC | 5 | $8,162 |
| CSL Behring | 11 | $3,251 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART HYTRULO$8,551
- THYMOGLOBULIN$8,162
How this compares
$20,100 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 30 | $49,695 |
| Mycophenolic AcidMycophenolate Sodium | 30 | $10,562 |
| Valganciclovir Hcl | 15 | $9,501 |
| Atovaquone | 11 | $8,467 |
| Tacrolimus | 47 | $4,761 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 706 | $2,930 |
| Leflunomide | 14 | $1,448 |
| Nifedipine ErNifedipine | 40 | $1,423 |
| Mycophenolate Mofetil | 27 | $1,111 |
| Prednisone | 87 | $650 |
| Dapsone | 11 | $522 |
| Carvedilol | 32 | $325 |
| Pantoprazole Sodium | 20 | $247 |
| Enalapril Maleate | 24 | $232 |
| Metoprolol Succinate | 18 | $162 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Columbus
- Brad RovinColumbus$379K
- Samir ParikhColumbus$145K
- Isabelle AyoubColumbus$116K
- Anil AgarwalColumbus$99K
- Karim AttiaColumbus$43K
- Rima KangColumbus$28K
- Salem AlmaaniColumbus$21K
- Naveen SingriColumbus$11K
- Jessica GrecoColumbus$11K
- Jason ProsekColumbus$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.